Profile data is unavailable for this security.
About the company
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).
- Revenue in AUD (TTM)502.55m
- Net income in AUD5.21m
- Incorporated2017
- Employees234.00
- LocationTelix Pharmaceuticals LtdSuite 401 55 Flemington RoadNorth MelbourneMELBOURNE 3051AustraliaAUS
- Websitehttps://telixpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | TLX:ASX since announced | Transaction value |
|---|---|---|
| ARTMS Inc | 27.91% | 82.00m |
| IsoTherapeutics Group LLC | 39.23% | 13.00m |
| Lightpoint Medical Ltd | 31.44% | 35.00m |
Data delayed at least 20 minutes, as of May 24 2024 03:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiamen Amoytop Biotech Co Ltd | 464.46m | 125.19m | 4.84bn | 1.96k | 38.67 | 11.57 | -- | 10.42 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Joincare Pharmaceutical Group Ind. Co. | 3.43bn | 296.21m | 4.97bn | 14.37k | 16.64 | 1.67 | -- | 1.45 | 0.7676 | 0.7676 | 8.86 | 7.63 | 0.4522 | 2.36 | 5.57 | 1,143,551.00 | 7.98 | 8.46 | 16.51 | 18.84 | 61.23 | 62.72 | 17.64 | 17.00 | 2.11 | -- | 0.2247 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| Syngene International Ltd | 633.17m | 92.56m | 5.10bn | 6.85k | 55.24 | 6.59 | 30.03 | 8.06 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Shanghai Junshi Biosciences Co Ltd | 339.68m | -422.05m | 5.22bn | 2.57k | -- | 4.20 | -- | 15.36 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Glenmark Pharmaceuticals Ltd | 2.13bn | -223.42m | 5.25bn | 15.56k | -- | -- | -- | 2.46 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
| Telix Pharmaceuticals Ltd | 502.55m | 5.21m | 5.27bn | 234.00 | 1,116.77 | 34.31 | 441.07 | 10.49 | 0.0141 | 0.0141 | 1.55 | 0.46 | 1.54 | 14.59 | 9.65 | -- | 1.59 | -29.21 | 2.54 | -40.27 | 62.56 | 61.64 | 1.04 | -37.14 | 1.32 | 24.03 | 0.1049 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| HUTCHMED (China) Ltd | 1.27bn | 152.18m | 5.28bn | 1.99k | 34.96 | 4.79 | 32.02 | 4.18 | 0.8967 | 0.8967 | 7.61 | 6.54 | 0.7258 | 7.19 | 7.69 | 3,289,778.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| Santen Pharmaceutical Co Ltd | 2.91bn | 256.63m | 5.36bn | 4.14k | 20.90 | 1.81 | 12.39 | 1.84 | 73.11 | 73.11 | 830.17 | 842.64 | 0.7048 | 2.99 | 3.11 | -- | 6.23 | 3.31 | 7.90 | 4.10 | 59.18 | 59.73 | 8.84 | 5.21 | 2.08 | 5.12 | 0.16 | 81.86 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
| Gland Pharma Ltd | 1.03bn | 140.20m | 5.36bn | 4.59k | 38.24 | 3.39 | 26.44 | 5.21 | 46.89 | 46.89 | 343.86 | 529.65 | 0.5828 | 1.21 | 4.12 | -- | 7.95 | 13.23 | 8.92 | 14.56 | 61.64 | 55.88 | 13.64 | 22.92 | 2.85 | 37.73 | 0.0409 | -- | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 1.83bn | 193.68m | 5.42bn | 8.22k | 27.45 | 3.05 | -- | 2.97 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Ajanta Pharma Ltd | 763.87m | 148.13m | 5.44bn | 7.71k | 36.72 | 8.40 | 31.48 | 7.12 | 64.79 | 64.79 | 334.10 | 283.32 | 0.9034 | 1.30 | 3.65 | -- | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.51 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 15.18 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| Shanghai Allist Pharmaceuticals Co Ltd | 518.33m | 190.96m | 5.56bn | 1.04k | 29.11 | 6.17 | -- | 10.73 | 2.03 | 2.03 | 5.52 | 9.60 | 0.6091 | 3.16 | 10.51 | 2,379,802.00 | 22.44 | 0.6405 | 24.19 | 0.6933 | 94.48 | 96.42 | 36.84 | 2.54 | 8.22 | -- | 0.0004 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Bluestar Adisseo Co | 2.82bn | 68.34m | 5.60bn | 2.73k | 81.95 | 1.78 | -- | 1.98 | 0.1222 | 0.1222 | 5.04 | 5.63 | 0.6286 | 4.67 | 7.33 | 4,947,799.00 | 1.52 | 5.28 | 1.85 | 6.94 | 23.81 | 30.31 | 2.42 | 8.76 | 1.04 | 4.30 | 0.1325 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Kangmei Pharmaceutical Co Ltd | 1.03bn | 33.46m | 5.61bn | 4.41k | 166.81 | 3.79 | -- | 5.45 | 0.0116 | 0.0116 | 0.3577 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
Data as of May 24 2024. Currency figures normalised to Telix Pharmaceuticals Ltd's reporting currency: Australian Dollar AUD
9.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 09 May 2024 | 9.71m | 2.94% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 5.21m | 1.58% |
| Vanguard Investments Australia Ltd.as of 30 Apr 2024 | 4.83m | 1.46% |
| BlackRock Fund Advisorsas of 09 May 2024 | 3.14m | 0.95% |
| Netwealth Investments Ltd.as of 24 Jan 2024 | 1.94m | 0.59% |
| BetaShares Capital Ltd.as of 30 Apr 2024 | 1.54m | 0.47% |
| Milford Australia Pty Ltd.as of 31 Mar 2024 | 1.18m | 0.36% |
| Platinum Investment Management Ltd.as of 31 Mar 2024 | 1.05m | 0.32% |
| Portland Investment Counsel, Inc.as of 30 Sep 2023 | 1.04m | 0.32% |
| BlackRock Asset Management North Asia Ltd.as of 30 Apr 2024 | 840.68k | 0.25% |
More ▼
Data from 31 Dec 2023 - 16 May 2024Source: FactSet Research Systems Inc.
